LLC cells were injected subcutaneously into wild-type C57BL/6 mice which were subsequently treated either with vehicle or an antibody against murine VEGF (B20, Genentech) or BI-88016 plus B20 (BI-880 effectively binds to both human and murine Ang2 and human but not murine VEGF) or B20 combined with depletion of tumour-infiltrating neutrophils using an anti-Ly6G antibody (Fig. 5a). This evidence concerns the gene VEGFA and neoplasm.